[Metastatic non-small cell lung cancer in the elderly and immunotherapy. To treat or not to treat?].

Lung cancer is a common disease with a high mortality rate. It is often diagnosed at an advanced stage, with a median survival of 12 to 16 months. Immune checkpoint inhibitors are part of the first-line therapeutic armoury in metastatic stages. They have been shown to improve overall survival, including in patients aged 64 to 75, but the results are less clear in older patients, who are underrepresented in clinical trials. Although the management of adverse events associated with these treatments is now well protocolized, the accumulation of toxicities, even low-grade toxicities, can have an adverse impact on the quality of life of the most frail elderly patients. Geriatric assessment is essential for adapting treatments and anticipating adverse effects.